ST 1535

Drug Profile

ST 1535

Alternative Names: ST1535

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator sigma-tau SpA
  • Class Antiparkinsonians; Purines; Triazoles
  • Mechanism of Action Adenosine A2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Neurodegenerative disorders; Parkinson's disease

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Neurodegenerative-disorders in Italy (PO)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Parkinson's-disease in Italy (PO)
  • 30 Jul 2009 Phase-I clinical trials in Parkinson's disease in Italy (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top